Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02774291
Recruitment Status : Unknown
Verified March 2020 by Ira Braunschweig, Albert Einstein College of Medicine.
Recruitment status was:  Recruiting
First Posted : May 17, 2016
Last Update Posted : March 6, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ira Braunschweig, Albert Einstein College of Medicine

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Unknown
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 6, 2021
September 1, 2021